... are needed to quantify even mild stages of dysfunction of the activities of daily living (ADL). Objectives: In this pilot study, home-based physical behavior was assessed to examine whether it is possible to distinguish mild cognitive impairment (PD-MCI) from PDD. Methods: Fifty-five patients with mild...

... individuals were included [324 healthy controls, 408 patients with mild cognitive impairment (MCI) and 277 patients with AD]. Magnetic resonance images were segmented using FreeSurfer, and the BV/CSF index was calculated and studied both cross-sectionally and longitudinally (1-year follow-up). Both AD...

...Elisabeth Kasper; Kolja Zydatiss; Christina Schuster; Judith Machts; Daniel Bittner; Jörn Kaufmann; Reiner Benecke; Stefan Vielhaber; Stefan Teipel; Johannes Prudlo Background/Aims: A substantial proportion of amyotrophic lateral sclerosis (ALS) patients develop cognitive impairments. Longitudinal...

.... Cognition Alzheimer’s disease p-tau Amyloid-β Cerebrospinal fluid Functional connectivity Alzheimer's disease (AD) is characterized by two distinct pathological features, namely the intracellular accumulation of hyperphosphorylated tau (p-tau) in the form of neurofibrillary tangles...

... subjects and 17 age-matched controls. In PD subjects, symptoms were assessed with the Unified Parkinson’s Disease Rating Scale and the Hoehn and Yahr scale. Cognition in both groups was assessed by a neuropsychological battery. Olfactory identification and sensitivity was evaluated with the Sniffin’ Sticks...

... to in the content or advertisements. Alzheimer’s disease Prodromal Alzheimer’s disease Preclinical Alzheimer’s disease Cognition Cerebrospinal fluid Amyloid Neuropsychology 22 06 2011 3 09 2011 7 12 2011 Diseases Neurodegenerative Dis 2012;10:158 160 DOI: 10.1159/000332806...

... will focus on the effects of DA agonists on depressive and cognitive symptoms of PD. Dopamine agonists Parkinson’s disease Depression Cognition Functional imaging 12 3 2010 © 2010 S. Karger AG, Basel 2010 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part...

... to patients with dementia. With multifactorial therapies, combining different drugs, it is possible to slow down cognitive deterioration in parallel with improvement in noncognitive symptoms; however, the association of the APOE-4 allele with specific genetic variants of other genes negatively modulates...

...Abraham Fisher The M1 muscarinic receptor (M1 mAChR) is a therapeutic target in Alzheimer’s disease (AD) and the M1-selective muscarinic agonists AF102B, AF150(S) and AF267B are cognitive enhancers and potential disease modifiers. Notably, AF267B decreased cerebrospinal fluid β-amyloid (Aβ 40...